RedHill Biopharma net loss widens 48% to USD 6.1 million in first half 2026
Bitget2026/09/30 20:08- RedHill Biopharma posted a net loss of USD 6.1 million for the six months ended June 30, 2026, widening from USD 4.1 million.
- Loss from continuing operations widened to USD 5.72 million from USD 2.94 million, while operating loss increased to USD 4.13 million.
- Financial expenses rose to USD 1.61 million from USD 849,000, while revenue was nil versus USD 286,000.
- Cash and cash equivalents totaled USD 5.16 million at June 30, 2026, and net cash used in operating activities was USD 4.56 million.
- Strategic reset includes buying commercialization rights to Rebyota and Clenpiq for USD 12 million, funded by a USD 18 million Talicia divestment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro gains against Canadian Dollar ahead of Eurozone HICP data
Major European stock indices open collectively higher
Broadcom (AVGO.US) syndicate begins raising 60 billions USD to supply chip "ammunition" for companies like Anthropic
According to informed sources, Broadcom's Wall Street syndicate is initiating the raising of $60 billion in new financing to purchase artificial intelligence (AI) chips, with beneficiaries including Anthropic PBC and other companies.
BICO completes integration of Cellenion into SCIENION, retires Cellenion brand
Crypto prices
More
